Eli Lilly First Quarter 2025 Earnings: EPS Misses Expectations

Simply Wall St · 05/06/2025 13:15

Eli Lilly (NYSE:LLY) First Quarter 2025 Results

Key Financial Results

  • Revenue: US$12.7b (up 45% from 1Q 2024).
  • Net income: US$2.76b (up 23% from 1Q 2024).
  • Profit margin: 22% (down from 26% in 1Q 2024).
  • EPS: US$3.07 (up from US$2.49 in 1Q 2024).
Our free stock report includes 2 warning signs investors should be aware of before investing in Eli Lilly. Read for free now.
earnings-and-revenue-growth
NYSE:LLY Earnings and Revenue Growth May 6th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eli Lilly EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 26%.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 6.4% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Eli Lilly (including 1 which is concerning).